Loading clinical trials...
Loading clinical trials...
A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
Conditions
Interventions
Nivolumab
Ipilimumab
Locations
6
United States
Columbia University Medical Center
New York, New York, United States
Tom Baker Cancer Centre
Calgary, Alberta, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Start Date
March 11, 2019
Primary Completion Date
June 1, 2021
Completion Date
February 9, 2022
Last Updated
February 22, 2024
NCT07360314
NCT07539285
NCT07403721
NCT07524348
NCT03093116
NCT06898450
Lead Sponsor
Canadian Cancer Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions